Search results

The Detection & Imaging group builds on ANSTO’s 70-year history of scientific achievements and contributions in meeting the nuclear needs of industry, globally.

During the scheduled shutdown of the OPAL multi-purpose reactor, an ANSTO engineering and project team has installed a new safety shutdown instrumentation and control system (I&C).

Recent studies led by the University of Melbourne have revealed that the Palawa people’s ancient land stewardship techniques have profoundly shaped the landscape of western Lutruwita, within the traditional territories located in Tasmania.

ANSTO Synroc® is constructing an Australian radioactive waste treatment facility for the by-products of Molybdenum-99 (Mo-99) production.

On this page you will find useful information about applying for a position at ANSTO and some tips on how you can prepare for an interview. 

Investigators have verified and quantified the relationship between the Earth’s land biosphere and changes in temperature and provided evidence that temperature impacts the cycling of carbon between land, ocean and the atmosphere.

PFAS chemicals in packaging pose serious environmental and health risks, but Australia’s packaging industry is leading the way to phase them out. Backed by cutting-edge nuclear science, industry-led action is creating safer packaging solutions for all Australians.

Investigations of various aspects of magnetism can be conducted on all neutron-scattering instruments at OPAL.

ANSTO offers reliable and traceable calibration services for radiation survey meters, contamination monitors and electronic personal dosimeters.

ANSTO's Chief Nuclear Officer shares insights on the safe management of Australia's nuclear waste.

In accordance with the Trust Deed, the United Uranium Scholarship is awarded to ‘promising young scientists’ from any Australian organisation or institution whose research or work is in the field of nuclear energy.

ANSTO’s nuclear medicine processing and distribution facility assembles, loads, tests and distributes a range of nuclear medicine products, including Mo-99. The Mo-99 is dispensed into an ANSTO radiopharmaceutical Gentech® Generator where it decays to Tc-99m.

ANSTO has contributed to research on a novel therapeutic option for combatting antimicrobial-resistant Gram-negative bacteria, known as superbugs.

A dedicated team of radiation specialists from the Australian Nuclear Science and Technology Organisation (ANSTO) are behind the successful detection and rapid retrieval of a missing radioactive source in outback Western Australia.

Ongoing media statements relating to nuclear medicine production.

Australia’s Open Pool Australian Lightwater (OPAL) reactor is a state-of-the-art 20 megawatt multi-purpose reactor that uses low enriched uranium (LEU) fuel to achieve a range of  activities to benefit human health, enable research to support a more sustainable environment and provide innovative solutions for industry.